Graig Suvannavejh Analyst PerformanceAnalyst at The Goldman Sachs GroupGraig Suvannavejh is a stock analyst at The Goldman Sachs Group in the healthcare sector, covering 29 publicly traded companies. Over the past year, Graig Suvannavejh has issued 76 stock ratings, including buy, hold, and sell recommendations. While full access to Graig Suvannavejh's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Graig Suvannavejh's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings103 Last 7 YearsBuy Recommendations84.81% 67 Buy RatingsCompanies Covered29 Unique Companies Ratings Distribution79RatingsDistribution of strong buy, buy, hold, and sell ratings by Graig Suvannavejh.RatingPercentageCount Strong Buy0.0%0 ratings Buy84.8%67 ratings Hold13.9%11 ratings Sell1.3%1 ratingsOut of 79 total stock ratings issued by Graig Suvannavejh at The Goldman Sachs Group, the majority (84.8%) have been Buy recommendations, followed by 13.9% Hold and 1.3% Sell.Best & Worst CallsBest Call0000.0%AMLXApr 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%ALECJul 2021Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ29 companiesGraig Suvannavejh, an analyst at The Goldman Sachs Group, currently covers 29 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare29 companies100.0%Graig Suvannavejh of The Goldman Sachs Group specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY21 companies72.4%PHARMACEUTICALS8 companies27.6% Graig Suvannavejh's Ratings History at The Goldman Sachs Group Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsLONAAthira Pharma8/19/2026Lower Price Target$8.15$15.00Outperform$0.0000.00% ROIAMLXAmylyx Pharmaceuticals8/18/2026Boost Price Target$35.11$42.00Outperform$0.0000.00% ROIAMLXAmylyx Pharmaceuticals8/17/2026Boost Price Target$21.63$30.00Outperform$0.0000.00% ROIBLTEBelite Bio8/14/2026Set Price Target$166.26$220.00$0.0000.00% ROICRBPCorbus Pharmaceuticals8/13/2026Set Price Target$9.76$33.00$0.0000.00% ROIAXSMAxsome Therapeutics8/12/2026Boost Price Target$215.77$316.00Outperform$0.0000.00% ROIVSTMVerastem8/10/2026Set Price Target$6.82$13.00Outperform$0.0000.00% ROIIMCRImmunocore8/3/2026Boost Price Target$33.81$35.00Neutral$0.0000.00% ROITARSTarsus Pharmaceuticals7/31/2026Lower Price Target$58.71$98.00Outperform$0.0000.00% ROIHRMYHarmony Biosciences7/31/2026Boost Price Target$34.79$51.00Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. AXSMAxsome Therapeutics7/31/2026Lower Price Target$219.17$306.00Outperform$0.0000.00% ROIAMLXAmylyx Pharmaceuticals7/20/2026Boost Price Target$17.75$24.00Outperform$0.0000.00% ROIZNTLZentalis Pharmaceuticals7/17/2026Initiated Coverage$4.57$8.00Outperform$0.0000.00% ROICRBPCorbus Pharmaceuticals6/23/2026Lower Price Target$8.51$34.00Outperform$0.0000.00% ROINMRANeumora Therapeutics6/18/2026Lower Price Target$1.48$4.00Outperform$0.0000.00% ROIINSMInsmed6/16/2026Set Price Target$97.46$192.00$0.0000.00% ROIBLTEBelite Bio5/26/2026Lower Price Target$137.30$215.00Outperform$0.0000.00% ROICRBPCorbus Pharmaceuticals5/22/2026Boost Price Target$11.51$44.00Outperform$0.0000.00% ROIVSTMVerastem5/14/2026Lower Price Target$4.72$14.00Outperform$0.0000.00% ROIIDYAIDEAYA Biosciences5/7/2026Lower Price Target$28.74$50.00Outperform$0.0000.00% ROIAXSMAxsome Therapeutics5/5/2026Boost Price Target$224.03$310.00Outperform$0.0000.00% ROIAMLXAmylyx Pharmaceuticals4/28/2026Boost Price Target$16.88$21.00Outperform$0.0000.00% ROIAPLSApellis Pharmaceuticals4/2/2026Boost Price Target$40.39$41.00Neutral$0.0000.00% ROIIMMXImmix Biopharma3/30/2026Boost Price Target$8.27$15.00Outperform$0.0000.00% ROIINSMInsmed3/25/2026Boost Price Target$145.11$206.00Outperform$0.0000.00% ROIAPLSApellis Pharmaceuticals3/5/2026Boost Price Target$19.86$20.00Neutral$0.0000.00% ROIPVLAPalvella Therapeutics2/25/2026Boost Price Target$122.56$250.00Outperform$0.0000.00% ROIINSMInsmed2/24/2026Lower Price Target$159.03$204.00Outperform$0.0000.00% ROIAXSMAxsome Therapeutics2/19/2026Set Price Target$184.74$230.00$0.0000.00% ROIVSTMVerastem2/19/2026Set Price Target$5.78$18.00$0.0000.00% ROIINSMInsmed2/19/2026Set Price Target$151.11$211.00$0.0000.00% ROIIMTXImmatics2/19/2026Set Price Target$9.95$25.00$0.0000.00% ROIHRMYHarmony Biosciences2/19/2026Set Price Target$35.23$50.00$0.0000.00% ROIBLTEBelite Bio2/19/2026Set Price Target$173.91$223.00$0.0000.00% ROILONAAthira Pharma2/19/2026Upgrade$4.76$10.00Outperform$0.0000.00% ROIIMMXImmix Biopharma2/9/2026Initiated Coverage$6.74$14.00Outperform$0.0000.00% ROIIMMXImmix Biopharma2/9/2026Initiated Coverage$6.42$14.00Outperform$0.0000.00% ROICRVSCorvus Pharmaceuticals1/29/2026Set Price Target$20.54$30.00$0.0000.00% ROIERASErasca1/27/2026Initiated Coverage$9.95$16.00Outperform$0.0000.00% ROIPVLAPalvella Therapeutics1/7/2026Initiated Coverage$90.43$205.00Outperform$0.0000.00% ROIA weekly dividend fund holding Nvidia and Palantir (Ad)CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names distributes income every single Thursday, with payouts reported as high as $1,051 a month. Chief Income Strategist Tim Plaehn breaks down the fund's real Thursday distribution history, how the income is generated, and how to buy it in any brokerage account.Watch the free presentation before this Thursday's payoutNMRANeumora Therapeutics1/5/2026Set Price Target$1.69$6.00$0.0000.00% ROIAXSMAxsome Therapeutics12/31/2025Set Price Target$183.34$217.00$0.0000.00% ROIINSMInsmed12/18/2025Set Price Target$165.73$212.00$0.0000.00% ROIERASErasca12/9/2025Boost Price Target$3.34$5.00Outperform$0.0000.00% ROITERNTerns Pharmaceuticals12/9/2025Boost Price Target$40.23$54.00Outperform$0.0000.00% ROIHALOHalozyme Therapeutics12/4/2025Reiterated Rating$64.66$56.00Sell$0.0000.00% ROIBLTEBelite Bio12/2/2025Set Price Target$154.02$194.00Outperform$0.0000.00% ROIBLTEBelite Bio12/2/2025Upgrade$150.84$194.00Outperform$0.0000.00% ROIHRMYHarmony Biosciences12/1/2025Boost Price Target$35.26$46.00Outperform$0.0000.00% ROIINSMInsmed12/1/2025Boost Price Target$206.43$256.00Outperform$0.0000.00% ROITERNTerns Pharmaceuticals11/28/2025Set Price Target$28.75$33.00$0.0000.00% ROITARSTarsus Pharmaceuticals11/20/2025Initiated Coverage$77.11$100.00Outperform$0.0000.00% ROIBLTEBelite Bio11/20/2025Initiated Coverage$120.36$105.00Neutral$0.0000.00% ROIIMTXImmatics11/19/2025Boost Price Target$10.33$23.00Outperform$0.0000.00% ROIHALOHalozyme Therapeutics11/18/2025Boost Price Target$70.20$56.00Neutral$0.0000.00% ROITERNTerns Pharmaceuticals11/13/2025Boost Price Target$20.30$33.00Outperform$0.0000.00% ROIIDYAIDEAYA Biosciences11/11/2025Boost Price Target$30.89$46.00Outperform$0.0000.00% ROIAXSMAxsome Therapeutics11/6/2025Boost Price Target$138.17$202.00Outperform$0.0000.00% ROIHRMYHarmony Biosciences11/6/2025Boost Price Target$30.66$39.00Outperform$0.0000.00% ROITERNTerns Pharmaceuticals11/4/2025Boost Price Target$18.19$32.00Outperform$0.0000.00% ROIAPLSApellis Pharmaceuticals11/3/2025Lower Price Target$21.47$19.00Neutral$0.0000.00% ROIVSTMVerastem10/29/2025Set Price Target$8.76$15.00$0.0000.00% ROIINSMInsmed10/29/2025Set Price Target$166.29$196.00$0.0000.00% ROIIMTXImmatics10/29/2025Set Price Target$10.36$19.00$0.0000.00% ROIHRMYHarmony Biosciences10/29/2025Set Price Target$28.97$36.00$0.0000.00% ROITERNTerns Pharmaceuticals10/22/2025Set Price Target$7.50$9.00$0.0000.00% ROIALECAlector10/22/2025Set Price Target$3.21$1.50Neutral$0.0000.00% ROIALECAlector10/22/2025Downgrade$1.61$1.50Neutral$0.0000.00% ROIVSTMVerastem10/21/2025Set Price Target$8.05$14.00$0.0000.00% ROIEYPTEyepoint Pharmaceuticals10/20/2025Set Price Target$11.63$28.00$0.0000.00% ROIKALAKALA BIO9/30/2025Set Price Target$88.60$75.00$0.0000.00% ROIKALAKALA BIO9/30/2025Downgrade$1.82Neutral$0.0000.00% ROIHRMYHarmony Biosciences9/25/2025Lower Price Target$26.48$35.00Outperform$0.0000.00% ROILONAAthira Pharma9/19/2025Set Price Target$3.91$4.00$0.0000.00% ROIIDYAIDEAYA Biosciences9/12/2025Boost Price Target$25.12$44.00Outperform$0.0000.00% ROIKALAKALA BIO9/8/2025Initiated Coverage$727.50$1,500.00Outperform$0.0000.00% ROIINSMInsmed8/13/2025Boost Price Target$122.00$165.00Outperform$000.0000.00% ROIALECAlector7/28/2025Upgrade$1.76$3.50Outperform$0.0000.00% ROINMRANeumora Therapeutics7/16/2025Boost Price Target$1.45$5.00Outperform$0.0000.00% ROIADAPAdaptimmune Therapeutics6/26/2025Downgrade$0.25$0.50Neutral$0.0000.00% ROIADVMAdverum Biotechnologies6/26/2025Lower Price Target$2.47$12.00Outperform$0.0000.00% ROIIMRXImmuneering6/18/2025Boost Price Target$2.18$10.00Outperform$0.0000.00% ROIINSMInsmed6/11/2025Boost Price Target$98.09$110.00Outperform$00.0000.00% ROICRVSCorvus Pharmaceuticals5/20/2025Set Price Target$3.57$11.00Outperform$00.0000.00% ROIEYPTEyepoint Pharmaceuticals5/16/2025Lower Price Target$5.93$26.00Outperform$00.0000.00% ROIHRMYHarmony Biosciences5/15/2025Boost Price Target$33.87$48.00Outperform$00.0000.00% ROIAPLSApellis Pharmaceuticals5/14/2025Lower Price Target$16.86$20.00Neutral$0.0000.00% ROIAMLXAmylyx Pharmaceuticals4/7/2025Upgrade$3.43$7.00Outperform$00.0000.00% ROIAXSMAxsome Therapeutics3/27/2025Boost Price Target$119.16$216.00Outperform$000.0000.00% ROIHRMYHarmony Biosciences3/18/2025Boost Price Target$34.32$44.00Outperform$00.0000.00% ROIMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown” (Ad)In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night. Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets.See Jim Rickards' full market warning and what it means for your portfolioAXSMAxsome Therapeutics2/26/2025Boost Price Target$129.67$212.00Outperform$000.0000.00% ROIHRMYHarmony Biosciences2/20/2025Lower Price Target$34.92$42.00Outperform$00.0000.00% ROIAXSMAxsome Therapeutics2/11/2025Boost Price Target$127.08$195.00Outperform$000.0000.00% ROIAXSMAxsome Therapeutics2/3/2025Boost Price Target$107.14$137.00Outperform$000.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageCitigroupUBS GroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftBMO Capital MarketsMizuho Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
